CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

HONG KONG, China and WILMINGTON, Del., Apr 1, 2024 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that on 31 March 2024, that the Group, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”…
Read More

Zaļā Josta - Reklāma